^
Association details:
| Biomarker: | CDK4 amplification |
|---|---|
| Cancer: | Liposarcoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma
Excerpt:
...Patients' tumors must also have evidence of CDK4 amplification by FISH....
Trial ID:
Source:
Title:
Phase 2 Trial of the CDK4 inhibitor Palbociclib (PD0332991) at 125 mg dose in Well-Differentiated or Dedifferentiated Liposarcoma
Excerpt:
60 patients with advanced WD/DDLS, age ≥ 18 years...Patients received oral palbociclib at 125mg daily for 21 days in 28-day cycles....All of the patients in the initial cohort had CDK4 amplification. In the expansion cohort, 5 patients had CDK4 amplification and the rest were not tested….In the initial cohort, 14 of the first 28 patients were progression free at 12 weeks...The overall PFS at 12 weeks was 57.2% (2-sided 95% CI: 42.4% – 68.8%). The median PFS was 17.9 weeks (2-sided 95% CI: 11.9 – 24.0 weeks).
DOI:
10.1001/jamaoncol.2016.0264
Source:
Title:
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Excerpt:
Treatment with the CDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
DOI:
10.1200/JCO.2012.46.5476
Trial ID:
